Tresiba Bolsters Novo Nordisk’s Japan Position
This article was originally published in PharmAsia News
Novo Nordisk’s diabetes market share in Japan is regaining ground as newer products Tresiba and Victoza carve out niches in the highly competitive sector.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.